Difference between revisions of "Lomustine (CCNU)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 24: Line 24:
 
[[Category:Drug index]]
 
[[Category:Drug index]]
 
[[Category:Chemotherapy]]
 
[[Category:Chemotherapy]]
[[Category:Oral chemotherapy]]
+
[[Category:Oral medications]]
  
 
[[Category:Nitrosureas]]
 
[[Category:Nitrosureas]]

Revision as of 17:07, 25 July 2017

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

Also known as

CCNU, MeCCNU.

  • In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.[5] Lomustine will be supplied as CCNU by NextSource Biotechnology.[6]

References